Sponsor
HIV Prevention Trials Network
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name HIV Prevention Trials Network appears in 32 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
32 shownDuo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated StrategyNCT07658976 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGPhase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PRNCT07288190 · lead sponsor · 2026-05-15
NOT_YET_RECRUITINGGetting to Zero Among HHI MSM in the American SouthNCT05075967 · lead sponsor · 2025-12-10
ENROLLING_BY_INVITATIONImproving HIV Prevention Among Heterosexual Men Seeking STI Services in MalawiNCT06200545 · lead sponsor · 2024-04-02
COMPLETEDTesting a Barbershop-based HIV Prevention Initiative Among MenNCT06148584 · lead sponsor · 2024-03-13
COMPLETEDINTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery UnitNCT04804072 · lead sponsor · 2021-06-02
COMPLETEDPre-Exposure Prophylaxis for Transgender Women in the US and South AmericaNCT04742491 · lead sponsor · 2021-03-26
COMPLETEDA Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in ZambiaNCT03025165 · lead sponsor · 2017-05-01
COMPLETEDUptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard StudyNCT02732730 · lead sponsor · 2016-10-12
COMPLETEDEnhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United StatesNCT02663219 · lead sponsor · 2016-06-06
COMPLETEDFeasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan AfricaNCT03201510 · lead sponsor · 2015-06-12
COMPLETEDIntegrated Treatment and Prevention for People Who Inject DrugsNCT02935296 · lead sponsor · 2015-02-04
COMPLETEDPopulation Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)NCT01900977 · lead sponsor · 2014-01-01
COMPLETEDHPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)NCT01808352 · lead sponsor · 2013-08-15
COMPLETEDThe ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)NCT01327651 · lead sponsor · 2011-08-01
COMPLETEDEffects of Cash Transfer for the Prevention of HIV in Young South African WomenNCT01233531 · lead sponsor · 2011-03-01
COMPLETEDDose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy VolunteersNCT01276600 · lead sponsor · 2011-01-01
COMPLETEDEvaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention StrategiesNCT01152918 · lead sponsor · 2010-09-01
COMPLETEDPreparing for International Prevention Trials Involving HIV-Infected Individuals in Care SettingsNCT01264185 · lead sponsor · 2010-04-01
COMPLETEDFeasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-InfectionNCT01197027 · lead sponsor · 2010-02-01
COMPLETEDFeasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With MenNCT00951249 · lead sponsor · 2009-07-01
COMPLETEDThe Women's HIV SeroIncidence Study (ISIS)NCT00995176 · lead sponsor · 2009-04-01
COMPLETEDHIV Incidence and Participation Retention in Pune, IndiaNCT00028119 · lead sponsor · 2002-08-01
COMPLETEDStudy of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · collaborator · 2023-12-13
ACTIVE_NOT_RECRUITINGStudy of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · collaborator · 2023-11-17
ACTIVE_NOT_RECRUITINGAnalytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP StudyNCT04801758 · collaborator · 2022-08-22
COMPLETEDAnalytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP StudyNCT04860323 · collaborator · 2021-05-28
COMPLETEDEvaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsNCT04212091 · collaborator · 2020-11-10
COMPLETEDEvaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenNCT01505114 · collaborator · 2012-06-01
COMPLETEDPreventing Sexual Transmission of HIV With Anti-HIV DrugsNCT00074581 · collaborator · 2005-02-01
COMPLETEDBufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in WomenNCT00074425 · collaborator · 2005-01-01
COMPLETEDCommunity Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and ThailandNCT00203749 · collaborator · 2004-12-01
COMPLETEDSponsor roles
lead sponsor23
collaborator9
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.